Skip to contentL
Lexicon Pharmaceuticals, Inc.
L
LXRXLexicon Pharmaceuticals, Inc. Q1 2013 · 10-Q
Revenue$277.00K$277.00K−23.1% vs Q1 2012 Net Income-$30.84M-$30.84MN/M vs Q1 2012 EPS Diluted-$0.42-$0.42N/M vs Q1 2012 Operating Income-$30,472,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Lexicon Pharmaceuticals, Inc. · CIK 1062822 · Engraved from SEC EDGAR
Free Cash Flowderived-$30,347,000N/M Margins · derivedOperating margin-11000.7%−3902.1 pt vs Q1 2012
Net margin-11131.8%−3916.8 pt vs Q1 2012
ended Mar 31, 2014 · filed May 8, 2014 · 38 d after period end